Cowen and Company’s BioNTech BNTX Stock Holding History

Cowen and Company’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-17,000	Closed	-$41.6K	–	53
2024 Q3	$41.6K	Buy	+17,000	New	+$1.56M	﹤0.01%	354

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Cowen and Company's BNTX Position: Q4 2024 in Review

Cowen and Company sold out of BioNTech (BNTX) in Q4 2024, closing a stake of 8,402 shares — an estimated $998K sold.

Cowen and Company first reported a position in BNTX in Q1 2020 and held it in 3 quarters. The position peaked at $998K in Q3 2024. 303 funds tracked by Wall St. Rank hold BNTX as of Q4 2024.

Cowen and Company reported no remaining BioNTech position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 8,402 BioNTech shares in Q4 2024, an estimated $998K.
Cowen and Company first reported a position in BioNTech in Q1 2020 and held it in 3 quarters.
Cowen and Company's BioNTech position peaked at $998K in Q3 2024.
303 funds tracked by Wall St. Rank held BioNTech as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.